April 1 - April 2
CAR-T therapy is set to revolutionize oncology pipelines and mark a new era for personalized medicine. With the recent approvals of Yescarta and Kymriah and the $11 billion acquisition of Kite, the race is on to lead the commercialization of safe, efficacious and accessible CAR-T therapy.
The fifth annual CAR-T congress USA is bringing together the leading pharmaceutical companies, the disruptive biotechs and pioneering academic institutions to assess emerging novel data and tackle the current challenges including antigen discovery, manufacturing scalability and efficacy.
Be part of the movement that engineers a strategy to reprogram the cancer treatments we know today.